Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Decitabine + Tretinoin |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Decitabine | Dacogen | 5-aza-2-deoxycytidine | DNMT inhibitor (Pan) 5 | Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov). |
| Tretinoin | Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA | Tretinoin is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Tretinoin is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KMT2A - MLLT3 | acute myeloid leukemia | sensitive | Decitabine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, combination of Tretinoin and Dacogen (decitabine) in acute myeloid leukemia cells harboring KMT2A-MLLT3 resulted in significant growth inhibition, and greatly induced myeloid differentiation as indicated by CD11b and C/EBPalpha expression, and downregulation of c-Myc, and in a murine cell model, resulted in greater upregulation of C/EBPalpha and growth inhibition, and increased apoptosis compared to Tretinoin alone in culture (PMID: 23063977). | 23063977 |
| KMT2A - AFF4 | leukemia | no benefit | Decitabine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment of Tretinoin and Dacogen (decitabine) in murine leukemic cells expressing a KMT2A-AFF4 fusion did not result in upregulation of Mac-1 and C/EBPalpha and resulted in similar growth compared to untreated cells in culture (PMID: 23063977). | 23063977 |
| KMT2A - AFF1 | acute myeloid leukemia | predicted - sensitive | Decitabine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment of Tretinoin and Dacogen (decitabine) resulted in growth inhibition in acute myeloid leukemia cells harboring a KMT2A-AFF1 fusion in cell culture (PMID: 23063977). | 23063977 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST